UNSPSC 51333003: Molindone

This classification denotes an antipsychotic agent with the molecular formula C16H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RT3Y3QMF8N, chemically known as 4h-indol-4-one, 3-ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)- but generally known as molindone, which bears US NIH Compound Identifier 23897. European Medicines Agency schedules Molindone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09042MIG.

UNSPSC 51333003 Molindone is a Commodity code that nominally refers to a specific antipsychotic medication, but recent state and local procurement activity under this code does not show solicitations for molindone itself. Instead, the code appears to be tagged to broader pharmaceutical procurement initiatives spanning naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local health agencies—including county health departments, state health and human services commissions, and cooperative purchasing alliances—are using this code to solicit pharmaceutical supply contracts that serve community health, emergency response, and employee health benefit programs. The work involves establishing supply agreements with manufacturers, managing distribution through authorized wholesalers, negotiating pricing structures, and ensuring compliance with FDA regulations, cGMP standards, and the Drug Supply Chain Security Act.

Recent activity spans multiple jurisdictions and procurement mechanisms. Seminole County, Florida issued an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2026. The Texas Health and Human Services Commission posted an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for self-insured state and employer health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP due March 26, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026 and pricing evaluation weighted heavily on cost competitiveness (75 percent) alongside administrative compliance and EDI capability. The geographic spread includes Florida, Texas, and the upper Midwest, with cooperative purchasing mechanisms extending activity across multiple state jurisdictions simultaneously.